Navigation Links
Kendle Invites You to Attend its First Quarter 2008 Earnings Conference Call and Webcast
Date:4/24/2008


CINCINNATI, April 24 /PRNewswire-FirstCall/ --

CALL DATE: Wednesday, May 7, 2008

TIME: 9:30 a.m. Eastern Time

HOST: Dr. Candace Kendle, Chairman and CEO

Kendle (Nasdaq: KNDL) will conduct a telephone conference call and simultaneous webcast on Wednesday, May 7 at 9:30 a.m. Eastern Time to discuss its financial results for the First Quarter ended March 31, 2008. A question and answer session will follow.

Webcast Instructions

To access the live webcast, go to http://www.kendle.com or http://www.videonewswire.com/event.asp?id=47950. Instructions for accessing the webcast are provided at both sites. The webcast will be archived at http://www.kendle.com (click on "Investors" and then "Events & Presentations") shortly after the call for on-demand replay through 5 p.m. Eastern Time on June 6, 2008. Please note that webcast participants will not be able to ask questions.

System requirements for the webcast include Windows Media Player software and at least a 28.8 Kbps connection to the Internet. Media Player is downloadable at no charge from http://www.microsoft.com/windows/windowsmedia/default.aspx.

Conference Call Instructions

To register (RSVP) for the telephone conference call, U.S. and Canadian participants should dial (800) 223-7104. Participants outside North America should dial (706) 645-6519.

To participate in the telephone conference call, interested parties in the United States and Canada should dial (800) 399-0069. Participants outside North America should dial (706) 643-3694. A replay will be available through 5 p.m. Eastern Time on June 6 by dialing (706) 645-9291 and entering conference ID number 41241978.

About Kendle

Kendle (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing drugs to market for the benefit of patients worldwide. As one of the fastest-growing global providers of Phase I-IV services we offer experience spanning 90 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges. Kendle was named "Top CRO to Work With" in the Thomson CenterWatch 2007 survey of U.S. investigative sites and "Best CRO" for 2007 and 2006 by leading global pharmaceutical publication Scrip World Pharmaceutical News.

Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 1200, Cincinnati, OH 45202, United States or from the company's Web site at http://www.kendle.com

(Logo: http://www.newscom.com/cgi-bin/prnh/20030429/KNDLLOGO )


'/>"/>
SOURCE Kendle
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Kendle to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference
2. Kendle Leaders Adopt 10b5-1 Trading Plans
3. Kendle to Present at the 29th Annual Raymond James Institutional Investors Conference
4. Kendle Hires Satish Tripathi, PhD, RAC as Vice President, Global Regulatory and Quality
5. Kendle to Present at the Wachovia 2008 Healthcare Conference
6. Kendle Appoints Former MHRA Head of Biologics as Principal Regulatory Affairs Consultant
7. Kendle Named Best CRO for Second Consecutive Year by Leading Global Pharmaceutical Publication Scrip
8. Kendle Invites You to Attend Its Third Quarter 2007 Earnings Conference Call and Webcast
9. Kendle to Present at the Natixis Bleichroeder Hidden Gems Conference
10. Kendle to Present at the UBS Global Life Sciences Conference
11. Kendle to Present at Bear Stearns 20th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... LONDON , March 28, 2017 ... to better understand Enzo Biochem and its partnering interests and ... since 2010 report provides an in-depth insight into the partnering ... On demand company reports are prepared upon purchase ... and company data. The report will be delivered ...
(Date:3/28/2017)... -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical ... metabolic and endocrine disorders, today announced that its chief ... a corporate presentation at H.C. Wainwright & Co.,s 1 ... 3, 2017 at the St. Regis Hotel in New ... as follows: H.C. Wainwright & ...
(Date:3/28/2017)... Durham, NC (PRWEB) , ... March 28, 2017 ... ... unwanted side effects and diminished effectiveness over time. A recent study published in ... treat PD by stimulating subventricular zone (SVZ) stem cells to produce more neural ...
(Date:3/28/2017)... NC (PRWEB) , ... March 28, 2017 , ... ... engaged in the development of a new orally administered treatment for Alzheimer’s disease ... , CEO John Didsbury states, “As we seek to uniquely treat the metabolic ...
Breaking Biology Technology:
(Date:3/27/2017)... March 27, 2017  Catholic Health Services (CHS) ... Systems Society (HIMSS) Analytics for achieving Stage 6 ... sm . In addition, CHS previously earned a ... using an electronic medical record (EMR). ... level of EMR usage in an outpatient setting.  ...
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based ... to 2022", published by MarketsandMarkets, the market is expected to be worth USD ... 2022. Continue Reading ... ... ...
(Date:3/22/2017)... YORK , March 21, 2017 ... Marketing Cloud used by retailers such as 1-800-Flowers ... its platform — Product Recommendations and Replenishment. Using Optimove,s ... give more personalized product and replenishment recommendations to ... but also on predictions of customer intent drawn ...
Breaking Biology News(10 mins):